Hepatitis Monthly

Published by: Kowsar

Calculation of Wiener Indices of Thiazolides: The Potent Inhibitors of Hepatitis B Virus and Hepatitis C Virus Replication

Mobeen Munir 1 , Shazia Rafique 2 , Amjad Ali 2 , Muhammad Idrees 2 , 3 and Shin Min Kang 4 , 5 , *
Authors Information
1 Division of Science and Technology, University of Education Lahore, Pakistan
2 Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan
3 Vice Chancellor Hazara University, Mansehra, Pakistan
4 Department of Mathematics RINS, Gyeongsang National University, Jinju, Korea
5 Center for General Education, China Medical University, Taichung, Taiwan
Article information
  • Hepatitis Monthly: April 2018, 18 (4); e67709
  • Published Online: March 26, 2018
  • Article Type: Research Article
  • Received: November 20, 2016
  • Revised: January 15, 2017
  • Accepted: December 20, 2017
  • DOI: 10.5812/hepatmon.67709

To Cite: Munir M, Rafique S, Ali A, Idrees M, Min Kang S. et al. Calculation of Wiener Indices of Thiazolides: The Potent Inhibitors of Hepatitis B Virus and Hepatitis C Virus Replication, Hepat Mon. 2018 ; 18(4):e67709. doi: 10.5812/hepatmon.67709.

Abstract
Copyright © 2018, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Dash S, Haque S, Joshi V, Prabhu R, Hazari S, Fermin C, et al. HCV-hepatocellular carcinoma: new findings and hope for effective treatment. Microsc Res Tech. 2005;68(3-4):130-48. doi: 10.1002/jemt.20227. [PubMed: 16276514].
  • 2. Decock S, Verslype C, Fevery J. Hepatitis C and insulin resistance: mutual interactions. A review. Acta Clin Belg. 2007;62(2):111-9. doi: 10.1179/acb.2007.019. [PubMed: 17547292].
  • 3. Jeffers L. Hepatocellular carcinoma: an emerging problem with hepatitis C. J Natl Med Assoc. 2000;92(8):369-71. [PubMed: 10992680].
  • 4. Manns M, Muir A. Telaprevir in hepatitis C genotype-1-Infected patients with prior known-response NA, viral breakthrough, or relapse to peg-interferon-alfa-2A/B and ribavirin therapy: SVR results of the PROVE3 study. J Hepatol. 2009;50(Suppl 1).
  • 5. Schinazi RF, Bassit L, Gavegnano C. HCV drug discovery aimed at viral eradication. J Viral Hepat. 2010;17(2):77-90. doi: 10.1111/j.1365-2893.2009.01246.x. [PubMed: 20040045].
  • 6. Elazar M, Liu M, McKenna SA, Liu P, Gehrig EA, Puglisi JD, et al. The anti-hepatitis C agent nitazoxanide induces phosphorylation of eukaryotic initiation factor 2alpha via protein kinase activated by double-stranded RNA activation. Gastroenterology. 2009;137(5):1827-35. doi: 10.1053/j.gastro.2009.07.056. [PubMed: 19664635].
  • 7. Romark Laboratories LC. Alinia_ (nitazoxanide) prescribing information. 2007.
  • 8. Rossignol JF, La Frazia S, Chiappa L, Ciucci A, Santoro MG. Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level. J Biol Chem. 2009;284(43):29798-808. doi: 10.1074/jbc.M109.029470. [PubMed: 19638339].
  • 9. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology. 2009;136(3):856-62. doi: 10.1053/j.gastro.2008.11.037. [PubMed: 19135998].
  • 10. Rossignol DA, Bradstreet JJ. Evidence of mitochondrial dysfunction in autism and implications for treatment. Am J Biochem Biotechnol. 2008;4(2):208-17.
  • 11. Korba BE, Elazar M, Lui P, Rossignol JF, Glenn JS. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide. Antimicrob Agents Chemother. 2008;52(11):4069-71. doi: 10.1128/AAC.00078-08. [PubMed: 18710916].
  • 12. Gonzalez-Diaz H. Network topological indices, drug metabolism, and distribution. Curr Drug Metab. 2010;11(4):283-4. [PubMed: 20545616].
  • 13. Yon C, Viswanathan P, Rossignol JF, Korba B. Mutations in HCV non-structural genes do not contribute to resistance to nitazoxanide in replicon-containing cells. Antiviral Res. 2011;91(3):233-40. doi: 10.1016/j.antiviral.2011.05.017. [PubMed: 21703309].
  • 14. Ashiru O, Howe JD, Butters TD. Nitazoxanide, an antiviral thiazolide, depletes ATP-sensitive intracellular Ca(2+) stores. Virology. 2014;462-463:135-48. doi: 10.1016/j.virol.2014.05.015. [PubMed: 24971706].
  • 15. Rouvray DH. The rich legacy of half a century of the Wiener index. Elsevier; 2002.
  • 16. Rouvray DH, King RB. Topology in chemistry: Discrete mathematics of molecules. Elsevier; 2002.
  • 17. Wiener H. Structural determination of paraffin boiling points. J Am Chem Soc. 1947;69(1):17-20. [PubMed: 20291038].
  • 18. Sarkanj B, Molnar M, Cacic M, Gille L. 4-Methyl-7-hydroxycoumarin antifungal and antioxidant activity enhancement by substitution with thiosemicarbazide and thiazolidinone moieties. Food Chem. 2013;139(1-4):488-95. doi: 10.1016/j.foodchem.2013.01.027. [PubMed: 23561135].
  • 19. Cacic M, Molnar M, Sarkanj B, Has-Schon E, Rajkovic V. Synthesis and antioxidant activity of some new coumarinyl-1,3-thiazolidine-4-ones. Molecules. 2010;15(10):6795-809. doi: 10.3390/molecules15106795. [PubMed: 20881932].
  • 20. Idris I, Warren G, Donnelly R. Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes. Arch Intern Med. 2012;172(13):1005-11. doi: 10.1001/archinternmed.2012.1938. [PubMed: 22688528].
  • 21. Singh S, Segal JB. Thiazolidinediones and macular edema: comment on "Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes". Arch Intern Med. 2012;172(13):1011-3. doi: 10.1001/archinternmed.2012.2461. [PubMed: 22688825].
  • 22. Isloor AM, Sunil D, Shetty P, Malladi S, Pai KSR, Maliyakkl N. Synthesis, characterization, anticancer, and antioxidant activity of some new thiazolidin-4-ones in MCF-7 cells. Med Chem Res. 2012;22(2):758-67. doi: 10.1007/s00044-012-0071-5.
  • 23. Yeh YN, Gutman I. On the sum of all distances in composite graphs. Discrete Math. 1994;135(1-3):359-65. doi: 10.1016/0012-365x(93)e0092-i.
  • 24. Rossignol JF, El-Gohary YM. Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial. Aliment Pharmacol Ther. 2006;24(10):1423-30. doi: 10.1111/j.1365-2036.2006.03128.x. [PubMed: 17081163].
  • 25. Hemphill A, Muller N, Muller J. Thiazolides, a novel class of anti-infective drugs, effective against viruses, bacteria, intracellular and extracellular protozoan parasites and proliferating mammalian cells. Anti Infect Agents. 2013;11(1):22-30.
  • 26. Gu Q, Yang X, Lin L, Li S, Li Q, Zhong S, et al. Genetic ablation of solute carrier family 7a3a leads to hepatic steatosis in zebrafish during fasting. Hepatology. 2014;60(6):1929-41. doi: 10.1002/hep.27356.
  • 27. Rossignol JF. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94-103. doi: 10.1016/j.antiviral.2014.07.014. [PubMed: 25108173].
  • 28. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007;51(3):868-76. doi: 10.1128/AAC.01159-06. [PubMed: 17158936].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments